表皮生长因子受体-酪氨酸激酶抑制剂联合化疗对非小细胞肺癌患者表皮生长因子受体基因突变的影响  

Effect of epidermal growth factor receptor-tyrosine kinase inhibitor combined with chemotherapy on epidermal growth factor receptor gene mutation in non-small cell lung cancer patients

作　　者：曾乾 彭述文 施敏 钟新云 龙瀛 李晓斌 ZENG Qian;PENG Shuwen;SHI Min;ZHONG Xinyun;LONG Ying;LI Xiaobin(Department of Oncology,the First Affiliated Hospital of Yichun University,Jiangxi Province,Yichun 336100,China)

机构地区：[1]宜春学院第一附属医院肿瘤科,江西宜春336100

出　　处：《中国当代医药》2025年第7期75-78,83,共5页China Modern Medicine

基　　金：江西省卫生健康委科技计划项目(202410946)。

摘　　要：目的探究非小细胞肺癌(NSCLC)患者应用表皮生长因子受体(EGFR)-酪氨酸激酶抑制剂(TKI)与化疗对其EGFR基因突变的影响。方法回顾性分析2022年1月1日至2024年1月1日宜春学院第一附属医院收治的60例NSCLC患者的临床资料,按治疗方法不同分为对照组(30例)与研究组(30例)。对照组给予ERFR-TKI治疗,研究组在此基础上联合化疗,比较两组的临床疗效、肺功能、肿瘤标志物、机体功能状态[Kamofsky功能状态评分(KPS)]、不良反应、EGER基因耐药位点T790M突变情况。结果研究组的疾病控制率高于对照组,治疗后用力肺活量及第1秒用力呼气容积均高于对照组,血清癌胚抗原、糖类抗原125水平均低于对照组,KPS评分、EGFR基因耐药位点T790M突变发生率低于对照组,差异有统计学意义(P<0.05)。两组患者的不良反应发生等级比较,差异无统计学意义(P>0.05)。结论NSCLC患者采用EGFR-TKI联合化疗治疗,效果显著,可有效改善患者肺功能、肿瘤标志物水平,提升机体功能状态,减少EGER基因突变情况的发生,且较为安全。Objective To explore the effect of epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitor(TKI)and chemotherapy on EGFR gene mutation in patients with non-small cell lung cancer(NSCLC).Methods The clinical data of 60 NSCLC patients admitted to the First Affiliated Hospital of Yicun University from January 1,2022 to January 1,2024 were retrospectively analyzed.According to different treatment methods,they were divided into control group(30 cases)and study group(30 cases).The control group was treated with ERFR-TKI,and the study group was treated with ERFR-TKI combined with chemotherapy.The clinical efficacy,lung function,tumor markers,body functional status(Kamofsky performance status[KPS]),adverse reactions and T790M mutation of EGER gene were compared between the two groups.Results The disease control rate of the study group was higher than that of the control group,the forced vital capacity and forced expiratory volume in one second after treatment were higher than those of the control group,the serum carcinoembryonic antigen and carbohydrate antigen 125 levels were lower than those of the control group,the KPS score and the incidence of EGFR gene resistance site T790M mutation were lower than those of the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the grade of adverse reactions between the two groups(P>0.05).Conclusion EGFR-TKI combined with chemotherapy is effective in the treatment of NSCLC patients,which can effectively improve the lung function,tumor marker levels,improve the functional status of the body,reduce the occurrence of EGER gene mutations,and is safe.

关 键 词：非小细胞肺癌 化疗 表皮生长因子受体-酪氨酸激酶抑制剂 表皮生长因子受体基因突变 

分 类 号：R734.2[医药卫生—肿瘤]